DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,970,975 | +1.7% | 16,005 | -2.9% | 0.41% | +3.8% |
| Q2 2023 | $3,905,363 | -14.8% | 16,491 | -9.3% | 0.40% | -19.3% |
| Q1 2023 | $4,583,989 | -7.2% | 18,187 | -2.2% | 0.49% | -13.4% |
| Q4 2022 | $4,937,342 | -99.9% | 18,602 | -4.0% | 0.57% | -6.7% |
| Q3 2022 | $5,004,110,000 | +4.6% | 19,374 | +2.7% | 0.61% | +3.7% |
| Q2 2022 | $4,783,668,000 | +5.7% | 18,869 | +22.3% | 0.59% | +33.4% |
| Q1 2022 | $4,526,375,000 | +2.8% | 15,431 | +15.3% | 0.44% | +7.8% |
| Q4 2021 | $4,402,153,000 | +28.8% | 13,380 | +19.2% | 0.41% | +14.6% |
| Q3 2021 | $3,417,339,000 | +8.6% | 11,225 | -4.3% | 0.36% | +7.6% |
| Q2 2021 | $3,146,521,000 | +20.3% | 11,725 | +0.9% | 0.33% | +4.4% |
| Q1 2021 | $2,616,555,000 | -0.8% | 11,625 | -2.1% | 0.32% | -8.6% |
| Q4 2020 | $2,637,912,000 | +2.3% | 11,875 | -0.8% | 0.35% | -9.9% |
| Q3 2020 | $2,578,576,000 | +15.5% | 11,975 | -5.1% | 0.38% | +0.8% |
| Q2 2020 | $2,232,479,000 | +19.7% | 12,625 | -6.3% | 0.38% | -3.3% |
| Q1 2020 | $1,865,075,000 | -29.9% | 13,475 | -22.2% | 0.40% | -9.6% |
| Q4 2019 | $2,659,041,000 | +4.5% | 17,325 | -1.7% | 0.44% | -5.2% |
| Q3 2019 | $2,545,579,000 | +0.8% | 17,625 | -0.3% | 0.46% | -2.3% |
| Q2 2019 | $2,526,111,000 | +4.4% | 17,675 | -3.5% | 0.47% | +0.2% |
| Q1 2019 | $2,419,267,000 | +22.5% | 18,325 | -4.3% | 0.47% | +8.3% |
| Q4 2018 | $1,975,160,000 | -6.1% | 19,154 | -1.0% | 0.44% | +10.7% |
| Q3 2018 | $2,102,462,000 | +7.4% | 19,349 | -2.5% | 0.39% | +1.3% |
| Q2 2018 | $1,958,403,000 | +0.7% | 19,846 | -0.1% | 0.39% | -4.0% |
| Q1 2018 | $1,945,570,000 | +6.6% | 19,871 | +1.0% | 0.40% | +4.7% |
| Q4 2017 | $1,825,881,000 | +0.1% | 19,671 | -7.5% | 0.39% | -3.3% |
| Q3 2017 | $1,824,643,000 | +0.1% | 21,271 | -1.5% | 0.40% | -3.2% |
| Q2 2017 | $1,822,503,000 | -1.8% | 21,596 | -0.5% | 0.41% | -3.3% |
| Q1 2017 | $1,855,676,000 | +8.1% | 21,696 | -1.6% | 0.43% | -0.2% |
| Q4 2016 | $1,716,076,000 | -7.0% | 22,046 | -6.4% | 0.43% | -8.8% |
| Q3 2016 | $1,845,786,000 | -27.6% | 23,546 | -6.7% | 0.47% | -29.7% |
| Q2 2016 | $2,549,846,000 | +1.6% | 25,246 | -4.6% | 0.67% | -1.3% |
| Q1 2016 | $2,510,565,000 | -1.5% | 26,466 | -3.6% | 0.68% | -1.5% |
| Q4 2015 | $2,549,185,000 | -0.5% | 27,446 | -8.7% | 0.68% | -9.0% |
| Q3 2015 | $2,562,691,000 | -0.4% | 30,075 | 0.0% | 0.75% | +13.4% |
| Q2 2015 | $2,574,119,000 | -2.3% | 30,075 | -3.1% | 0.66% | -4.3% |
| Q1 2015 | $2,635,211,000 | +5.5% | 31,039 | +6.5% | 0.69% | +1.9% |
| Q4 2014 | $2,497,504,000 | +135.0% | 29,139 | +115.8% | 0.68% | +133.2% |
| Q3 2014 | $1,062,855,000 | 0.0% | 13,500 | 0.0% | 0.29% | 0.0% |
| Q2 2014 | $1,062,855,000 | +24.3% | 13,500 | +18.4% | 0.29% | +15.9% |
| Q1 2014 | $855,000,000 | +281.9% | 11,400 | +293.1% | 0.25% | +260.0% |
| Q4 2013 | $223,880,000 | +2.2% | 2,900 | -8.2% | 0.07% | +12.9% |
| Q3 2013 | $219,051,000 | – | 3,160 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |